Novo Nordisk plugs hemorrhage with lucrative Biopharm unit restored to growth
![Photo: Novo Nordisk / PR](https://photos.watchmedier.dk/watchmedier/resize:fill:3840:0:0/plain/https://photos.watchmedier.dk/Images/article13192144.ece/ALTERNATES/schema-16_9/doc7h1qlymgeqvlmu5jasn.jpg)
The most lucrative unit of Novo Nordisk's business, Biopharm, has stopped capital from hemorrhaging and is in fact now restored to to growth.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.